Sanofi — a global pharmaceutical leader — is turning to technology to transform how treatments are developed and delivered to patients.
The pharma giant is partnering with companies to speed up drug discovery using AI. These efforts extend across its core R&D focus areas, including immunology and oncology.
The company is also leveraging partnerships and investments to enhance clinical trials and bring its 75+ clinical-stage projects to market more quickly. For example, Sanofi Ventures led a Series B round for Nucleai, which uses AI to help drugmakers understand how patients will respond to their drugs and, as a result, select the most suitable patients for clinical trials.
Beyond drug development, Sanofi is also making moves to help patients manage chronic diseases more effectively. It has maintained a strong focus on diabetes in particular, forming relationships with other companies to improve medication accessibility and adherence.
Using CB Insights data, we uncovered 4 of the most important strategic priorities highlighted by Sanofi’s investments and partnerships since Q1’22. We then categorized companies by their relationships with Sanofi across these priorities:
- AI-driven drug discovery
- Clinical trials tech
- Digital pharmacy tech
- Digital therapeutics
